Moheb M. Nasr, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Moheb M. Nasr, PhD


Moheb M. Nasr, PhD is a Pharmtech editorial advisory board (EAB) member

Moheb M. Nasr, PhD
Director,
Office of New Drug Quality
Assessment, CDER/FDA

Moheb Nasr is the director of the Office of New Drug Quality Assessment (ONDQA), in the Center for Drug Evaluation and Research (CDER), at the US Food and Drug Administration.  ONDQA is responsible for quality assessments (pre- and postmarketing) of new drugs regulated by CDER. Nasr obtained his PhD degree in Chemistry at the University of Minnesota in Minneapolis.

Nasr holds a BS degree in Pharmacy and a Master’s degree in Pharmaceutical Analysis, both from Cairo University, Egypt.  Nasr joined FDA in 1990, and assumed his current position in June 2003. He is leading the restructuring of the pharmaceutical quality assessment program at FDA. Nasr is a member of FDA’s Council on Pharmaceutical Quality, and is an elected fellow of the American Association of Pharmaceutical Scientists (AAPS).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here